SUPERNUS PHARMACEUTICALS INC - NOTE 0.625% 4/0

Historical Holders from Q1 2019 to Q2 2023

Type / Class
Debt / NOTE 0.625% 4/0
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of SUPERNUS PHARMACEUTICALS INC - NOTE 0.625% 4/0 across Reporting Periods

Period Principal Value Change Price (% of par) Investors
2023 Q2 $0 $0 -$392,925,321 0
2023 Q1 $393,849,741 $393,941,137 -$21,694,890 99.99% 40
2022 Q4 $415,075,000 $408,576,605 +$10,082,645 98.25% 45
2022 Q3 $398,553,065 $388,951,616 +$1,216,858 97.48% 39
2022 Q2 $397,707,000 $386,667,091 -$9,656,247 97.07% 39
2022 Q1 $407,409,784 $400,891,752 +$4,666,827 98.29% 41
2021 Q4 $402,317,675 $398,332,341 +$12,044,634 99.18% 39
2021 Q3 $388,952,675 $383,102,487 -$11,850,144 98.57% 41
2021 Q2 $390,734,324 $385,595,690 +$5,416,627 98.79% 43
2021 Q1 $385,799,649 $373,205,179 -$18,484,401 96.67% 44
2020 Q4 $405,389,800 $386,922,438 +$50,585,288 94.84% 44
2020 Q3 $352,061,084 $324,909,891 +$43,301,590 92.23% 41
2020 Q2 $305,602,088 $270,133,532 -$1,308,641 88.48% 41
2020 Q1 $316,716,637 $256,209,800 -$13,969,327 80.37% 42
2019 Q4 $324,677,440 $294,978,957 -$55,240,585 90.82% 42
2019 Q3 $353,229,426 $328,455,222 -$20,999,650 92.93% 31
2019 Q2 $373,094,912 $366,446,586 +$199,449,681 97.6% 35
2019 Q1 $171,088,000 $165,522,000 +$165,522,000 96.84% 9